Calgary, AB – TheNewswire - April 3, 2025 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has agreed to settle a portion, totalling $106,200, of arrears consulting fees owed to its CEO, Nicholas Karos (the “ Debt ”). UI is in process of applying to the TSX Venture Exchange (the “ TSXV ”) to... Read More